Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Apexigen
gptkb:Sana_Biotechnology Roche's_gene_therapy_assets |
| gptkbp:CEO |
gptkb:Vivek_Ramaswamy
|
| gptkbp:clinicalTrials |
rare diseases
autoimmune diseases chronic diseases multiple drug candidates infectious diseases metabolic diseases |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:employees |
over 300
|
| gptkbp:focus |
drug development
|
| gptkbp:focus_area |
neurology
oncology dermatology women's health urology |
| gptkbp:founded |
2014
|
| gptkbp:founder |
gptkb:Vivek_Ramaswamy
|
| gptkbp:headquarters |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Roivant Sciences
|
| gptkbp:investmentFocus |
2021
$1.1 billion venture capital strategic partnerships public offerings |
| gptkbp:leadership |
diverse team
|
| gptkbp:mission |
transforming the way medicines are developed
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Takeda_Pharmaceutical_Company gptkb:Bristol-Myers_Squibb gptkb:Pfizer Novartis |
| gptkbp:philosophy |
collaborative innovation
transparency in operations sustainability in practices patient-first approach agility in drug development |
| gptkbp:research_focus |
biomarkers
innovative therapies real-world evidence patient-centric solutions clinical endpoints |
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:stockExchange |
ROIV
|
| gptkbp:subsidiary |
gptkb:Axovant_Gene_Therapies
gptkb:Myovant_Sciences gptkb:Urovant_Sciences Dermavant_Sciences Enzyvant_Therapeutics |
| gptkbp:technology |
artificial intelligence
machine learning data science |
| gptkbp:website |
www.roivant.com
|